Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Sabatier, Renaud ^a   Finetti, Pascal ^a   Adelaide, José ^a   Guille, Arnaud ^a   Borg, Jean Paul ^a,b   Chaffanet, Max ^a   Lane, Lydie ^c,d   Birnbaum, Daniel ^a   Bertucci, François ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; C2ORF40 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA MICROARRAY; DOWN REGULATION; ECRG4 GENE; FEMALE; GENE DOSAGE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; BREAST TUMOR; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL;

BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 81155131661     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027656     Document Type: Article

References (28)

1. Su T, Liu H, Lu S, (1998) Cloning and identification of cDNA fragments related to human esophageal cancer. China J Oncol 20: 254-257.
2. Mirabeau O, Perlas E, Severini C, Audero E, Gascuel O.et al, (2007) Identification of novel peptide hormones in the human proteome by hidden Markov model screening. Genome Res 17: 320-327.
3. Gonzalez AM, Podvin S, Lin SY, Miller MC, Botfield H, et al. (2011) Ecrg4 expression and its product augurin in the choroid plexus: impact on fetal brain development, cerebrospinal fluid homeostasis and neuroprogenitor cell response to CNS injury. Fluids Barriers CNS 8: 6.
4. Kujuro Y, Suzuki N, Kondo T, (2010) Esophageal cancer-related gene 4 is a secreted inducer of cell senescence expressed by aged CNS precursor cells. Proc Natl Acad Sci USA 107: 8259-8264.
5. Yue CM, Deng DJ, Bi MX, Guo LP, Lu SH, (2003) Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol 9: 1174-1178.
6. Mori Y, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, et al. (2007) Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Oncol Rep 18: 981-985.
7. Li LW, Yu XY, Yang Y, Zhang CP, Guo LP, et al. (2009) Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer 125: 1505-1513.
8. Li W, Liu X, Zhang B, Qi D, Zhang L, (2010) Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion. J Exp Clin Cancer Res 29: 89.
9. Li LW, Li YY, Li XY, Zhang CP, Zhou Y, et al. (2011) 2.A novel tumor suppressor gene ECRG4 interacts directly with TMPRSS11A (ECRG1) to inhibit cancer cell growth in esophageal carcinoma. BMC Cancer 11: 52.
10. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, et al. (2009) Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest 27: 549-560.
11. Götze S, Feldhaus V, Traska T, Wolter M, Reifenberger G, et al. (2009) ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer 9: 447.
12. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, et al. (2007) Integrated profiling of basal and luminal breast cancers. Cancer Res 67: 11565-11575.
13. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, et al. (2006) Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66: 4636-4644.
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
15. Pawitan Y, Bjöhle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-964.
16. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555.
17. Ivshina AV, George J, Senko O, Mow B, Putti TC, et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301.
18. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, et al. (2007) Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8: 1071-1078.
19. Gonçalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, et al. (2011) Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat 127: 273-281.
20. Hu Z, Fan C, Oh D, Marron JS, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.
21. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121.
22. Ingenuity Pathways Analysis v8.0-2602 (IPA) (http://www.ingenuity.com).
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100: 229-235.
24. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, et al. (2010) COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38(Database issue) pp. D652-657.
25. Herman JG, Baylin SB, (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
26. Dworkin AM, Huang TH, Toland AE, (2009) Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Seminar Cancer Biol 19: 165-171.
27. Van der Auwera I, Bovie C, Svensson C, Trinh XB, Limame R, et al. (2010) Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer 10: 97.
28. Ozawa A, Lick AN, Lindberg I, (2011) Processing of proaugurin is required to suppress proliferation of tumor cell lines. Mol Endocrinol 25: 776-784.